Skip to main content
. 2018 Jan 9;25(3):309–322. doi: 10.1530/ERC-17-0455

Figure 3.

Figure 3

Mean changes from baseline (B) in frequency of bowel movements per day. The change in mean daily bowel movement (BM) frequency was assessed weekly over the double-blind treatment (DBT) and open-label extension (OLE) periods of the study. The dotted lines indicate the crossover of patients from either placebo or telotristat ethyl 250 mg 3 times per day (tid) to telotristat ethyl 500 mg tid in the OLE period.